Screener
Ionis Pharmaceuticals IONS Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $$47,704 | 28,082 |
| Accrued compensation | 50,293 | 116,236 |
| Accrued liabilities | 115,778 | 106,089 |
| Income taxes payable | 2,877 | 2,713 |
| 0 percent convertible senior notes due April 2026, net | - | 431,948 |
| Current portion of deferred contract revenue | 73,837 | 73,761 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's accrued expenses?
- Ionis Pharmaceuticals (IONS) reported accrued expenses of $50.29M in Q2 2026.
- How has Ionis Pharmaceuticals's accrued expenses changed year-over-year?
- Ionis Pharmaceuticals's accrued expenses increased by 8.0% year-over-year, from $46.56M to $50.29M.
- What is the long-term trend for Ionis Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's accrued expenses has grown at a 12.1% compound annual growth rate (CAGR), from $65.73M to $116.24M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Ionis Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude